DiaSorin stock outperforms Milan index with mid-September gain

Published on 09/18/2026 at 20:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DiaSorin stock gained about 4.4 percent over the latest week on Borsa Italiana, standing out against a weaker FTSE MIB as of September 18, 2026. The diagnostics group also shows a 4.5 percent positive move over the last 30 days while its one-year performance remains slightly negative.

Techniker im Reinraum bedienen automatisierte Diagnostikgeräte in modernem Biotech-Labor — Modernes Diagnostiklabor von DiaSorin S.p.A., ISIN IT0003497168, zeigt präzise Biotech-Produktion und klinische Fertigung, Illustration mit AI erstellt.

DiaSorin stock (ISIN IT0003497168) has emerged as one of the strongest performers on Borsa Italiana in mid-September, with the diagnostics specialist posting a weekly gain of about 4.4 percent as of September 18, 2026 and turning its 30-day performance positive despite a still slightly negative one-year track.

DiaSorin stands out on a weak FTSE MIB

According to MarketScreener on September 18, 2026, DiaSorin was the standout performer on the main Milan list, gaining 4.4 percent over the week while the FTSE MIB index finished the same period in the red.

The same overview from MarketScreener notes that DiaSorin’s performance over the last 30 days has moved back into positive territory, up 4.5 percent, whereas the stock’s annual performance remains modestly negative at about 1.0 percent, underscoring how the recent rebound has not yet fully offset prior weakness.

Recent price level and trading behavior

In the latest clearly dated session before September 18, 2026, DiaSorin shares closed at EUR 75.26 on Borsa Italiana on September 17, 2026, representing a marginal decline of 0.03 percent from the previous close and reflecting almost unchanged intraday trading on the Milan market.

Per a mid-September wrap cited in a recent overview of DiaSorin’s trading behavior, the price of EUR 75.26 as of September 17, 2026 left the shares in the mid-70 euro range, consistent with a relatively stable corridor in recent days and aligning with the gradual improvement indicated by the 4.4 percent weekly gain and 4.5 percent 30-day rise.

Stock remains a diagnostics play in Italy

DiaSorin remains positioned as a healthcare diagnostics company within the Italian market, and the mid-September data show that investors have recently been willing to pay a higher price for its shares compared with the levels seen a month ago, with the 4.5 percent 30-day increase contrasting with the still 1.0 percent negative annual performance reported by MarketScreener.

For investors, the key takeaway from the mid-September snapshot is that DiaSorin stock has begun to recoup part of its earlier losses, outperforming the broader FTSE MIB index over the latest week while still offering exposure to the Italian diagnostics segment rather than to the more cyclical sectors that weighed on the index’s overall result.

DiaSorin share price as of the last completed session

As of the last completed trading day with a clearly dated quote before September 18, 2026, DiaSorin stock closed at EUR 75.26 on Borsa Italiana on September 17, 2026, essentially flat on the session with a 0.03 percent slip versus the prior close and consolidating the recent 4.4 percent weekly gain within the mid-70 euro zone.